Clinical trials: Withdrawal
Fragile X Syndrome
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
There will be four study periods: Screening (up to 14 days in length), the Treatment Period (8 weeks), the Withdrawal Period (22 days), and Follow-up Period (up to 31 days).
- Trial name
- Harbor-C (NCT01325220)
- Testing
- arbaclofen
- Where
- 28 sites in United States
- Volunteers
- 172 people
- Sponsor
- Seaside Therapeutics, Inc.
Prader-Willi Syndrome
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of DCCR treatment.
- Trial name
- NCT03714373
- Testing
- DCCR
- Where
- 28 sites in United States, United Kingdom
- Volunteers
- 115 people
- Sponsor
- Soleno Therapeutics, Inc.
Narcolepsy
Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy
The purpose of this study is to assess the effectiveness and safety of the drug GSK189254 in treating patients with narcolepsy.
- Trial name
- NCT00366080
- Testing
- GSK189254
- Where
- 14 sites in Austria, Finland and 4 more
- Volunteers
- 69 people
- Sponsor
- GlaxoSmithKline
Hyperkalemia
Patiromer Trial in CKD Stage IIIB to V
This phase III, prospective, randomized, double-blind, placebo-controlled trial will primarily aim to compare the effects of patiromer and placebo on the rate of withdrawal or down-titration of RAAS inhibition therapy because of…
- Trial name
- NCT05786469
- Testing
- Veltassa Oral Powder Product
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Colitis, Ulcerative, Aminosalicylic Acid
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis
The purpose of this study is to determine whether aminosalicylic acid (ASA) can be safely withdrawn in patients with long-standing clinical inactive UC.
- Trial name
- NCT02537210
- Testing
- Mesalazine
- Where
- Hong Kong
- Volunteers
- 177 people
- Sponsor
- Chinese University of Hong Kong
Bipolar I Disorder, Mania
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e.
- Conditions
- Bipolar I Disorder, Mania, Depression
- Trial name
- NCT03573297
- Testing
- Cariprazine
- Where
- 108 sites in United States, Bulgaria and 9 more
- Volunteers
- 901 people
- Sponsor
- AbbVie
Psoriasis
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in the treatment of participants with moderate to severe psoriasis
- Trial name
- NCT06049810
- Testing
- IBI112
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Methamphetamine Use Disorder
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients…
- Trial name
- KARE (NCT06538285)
- Testing
- Ketamine, Psychotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Nicky Mehtani, MD, MPH
Heroin Dependence, Morphine Dependence
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.
- Conditions
- Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
- Trial name
- NCT00032968
- Testing
- Buprenorphine/naloxone
- Where
- 7 sites in United States
- Volunteers
- 341 people
- Sponsor
- University of California, Los Angeles
Type 2 Diabetes Mellitus, Atherosclerosis
Effects of 5-day Statin Withdrawal on Endothelial Progenitor Cells and Inflammatory Markers in Type 2 Diabetic Patients
Statins are commonly prescribed to lower cardiovascular risk in primary and secondary prevention. Despite their well known efficacy, statin withdrawal is a common event.
- Conditions
- Type 2 Diabetes Mellitus, Atherosclerosis, Dyslipidemia
- Trial name
- SStatin-EPC (NCT01600690)
- Testing
- Statin withdrawal
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- University of Padova
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Alcohol Withdrawal
Phenobarbital for Acute Alcohol Withdrawal
Intravenous phenobarbital in combination with a symptom-guided standardized lorazepam-based alcohol withdrawal protocol will be associated with decreased need for ICU admission, continuous lorazepam infusion and will not be…
- Trial name
- NCT01184417
- Testing
- 10 mg/kg IV phenobarbital in 100 ml saline
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jonathan Rosenson
Delirium, Psychomotor Agitation
Nicotine Replacement Therapy in the Intensive Care Unit
The purpose of this study is to determine whether transdermal nicotine replacement therapy is safe and effective for treating nicotine withdrawal symptoms in the critically ill smoking patient.
- Conditions
- Delirium, Psychomotor Agitation, Substance Withdrawal Syndrome, Nicotine Replacement Therapy
- Trial name
- NicGoWell (NCT01362959)
- Testing
- Transdermal nicotine patch, Cutaneous patch, containing no active substances
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people
- Sponsor
- Gelderse Vallei Hospital
Dementia
Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD)
Dementia is a chronic progressive mental disorder that adversely affects higher cortical functions, including cognition and behavior leading up to disability and dependence in daily life activities.
- Trial name
- WADAD (NCT05321680)
- Testing
- Treatment withdrawal
- Where
- Portugal
- Volunteers
- 16 people
- Sponsor
- Centro Hospitalar De São João, E.P.E.
Neonatal Abstinence Syndrome
How to Treat Opiate Withdrawal in Neonates
Three different drugs are used in a randomised, double blind, clinical multi-centre trial with three arms. Major objective is to investigate the duration of drug treatment based on the Finnegan score.
- Trial name
- NCT02810782
- Testing
- Phenobarbital, Chlorpromazine, Morphine
- Volunteers
- 120 people
- Sponsor
- University of Zurich
Cystic Fibrosis
Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)
The overall aim of this study is to find out whether taking regular inhaled steroids (eg Pulmicort, Flixotide, Becotide, Becloforte) is good for the lungs of children and adults with cystic fibrosis (CF).
- Trial name
- NCT00220259
- Where
- United Kingdom
- Volunteers
- 240 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Tobacco Use Disorder
Neural Substrates in Nicotine Withdrawal
This study will test the hypothesis that a medication called tolcapone (Brand Name: Tasmar) will help reduce cognitive problems that smokers experience when they quit.
- Trial name
- NCT01001520
- Testing
- Tolcapone
- Where
- United States
- Volunteers
- 218 people
- Sponsor
- University of Pennsylvania
Uremic Pruritus
A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)
Primary objective of this multicenter, double-blind, placebo controlled, randomized withdrawal study are to determine the effectiveness and safety of orally administered AC-820 in doses of 2.5 µg and 5.0 µg daily in patients with…
- Trial name
- AC120-8231 (NCT00793156)
- Testing
- Nalfurafine HCl 2.5 µg, Nalfurafine HCl 5.0 µg
- Volunteers
- 350 people
- Sponsor
- Acologix, Inc.
Opioid Use Disorder
A Study of SPG Block for Opioid Withdrawal
Medication is the most efficacious treatment of an opioid use disorder, including methadone, buprenorphine, and naltrexone. However, many patients experience withdrawal symptoms, which prevents them from being successfully…
- Trial name
- NCT04946656
- Testing
- sphenopalatine ganglion block
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- New York State Psychiatric Institute
Juvenile Idiopathic Arthritis (JIA)
Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis
The goal of this clinical trial is to learn whether children and adolescents with juvenile idiopathic arthritis (JIA) who have had inactive disease for a long time can safely discontinue treatment with a tumour necrosis factor…
- Trial name
- The Treat-JIA (NCT07904780)
- Testing
- Adalimumab, Etanercept, Golimumab
- Where
- 3 sites in Norway
- Volunteers
- 90 people
- Sponsor
- Oslo University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.